Patents Assigned to Protaffin Biotechnologie AG
  • FGFRI-BASED ANTAGONISTS WITH IMPROVED GLYCOSAMINOGLYCAN AFFINITY AND METHODS OF USING SAME
    Publication number: 20140073557
    Abstract: A novel approach for inhibiting FGF2/FGFR1-mediated signalling is presented which is based on FGFR1 mutations to introduce higher affinity for the natural GAG co-receptors into the soluble part of the FGF1 receptor, preferably into the D2/D3 domains.
    Type: Application
    Filed: March 16, 2012
    Publication date: March 13, 2014
    Applicant: PROTAFFIN BIOTECHNOLOGIE AG
    Inventors: Andreas Kungl, Martina Theuer
  • GLYCOSAMINOGLYCAN-ANTAGONISING MCP-1 MUTANTS AND METHODS OF USING SAME
    Publication number: 20130150303
    Abstract: Novel mutants of human monocyte chemoattractant protein 1 (MCP-1) with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type MCP-1, and their use for therapeutic treatment of inflammatory diseases.
    Type: Application
    Filed: December 17, 2012
    Publication date: June 13, 2013
    Applicant: PROTAFFIN BIOTECHNOLOGIE AG
    Inventor: Protaffin Biotechnologie AG
  • Glycosaminoglycan-antagonising MCP-1 mutants
    Patent number: 8337825
    Abstract: Novel mutants of human monocyte chemoattractant protein 1 (MCP-1) with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type MCP-1, and their use for therapeutic treatment of inflammatory diseases.
    Type: Grant
    Filed: July 21, 2008
    Date of Patent: December 25, 2012
    Assignee: Protaffin Biotechnologie AG
    Inventors: Andreas Kungl, Anna Maria Piccinini, Christian Weber
  • COMPOSITION FOR TREATMENT OF CXCL8-MEDIATED LUNG INFLAMMATION
    Publication number: 20120288474
    Abstract: The present invention provides a composition comprising a modified interleukin 8 (IL-8) having increased GAG binding affinity and further inhibited or down-regulated GPCR activity compared to the respective wild type IL-8 for use in preventing or treating lung inflammation with neutrophilic infiltration, for example for the prevention or treatment of chronic obstructive pulmonary disease, cystic fibrosis, severe asthma, bronchitis, broncheolitis, acute lung injury and acute respiratory distress syndrome.
    Type: Application
    Filed: September 13, 2010
    Publication date: November 15, 2012
    Applicant: PROTAFFIN BIOTECHNOLOGIE AG
    Inventors: Andreas Kungl, Jason Slingsby, Tiziana Adage, Angelika Rek
  • GLYCOSAMINOGLYCAN-ANTAGONISING MCP-I MUTANTS AND METHODS OF USING SAME
    Publication number: 20120046218
    Abstract: Novel mutants of human monocyte chemoattractant protein 1 (MCP-1) with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type MCP-1, and their use for therapeutic treatment of inflammatory diseases.
    Type: Application
    Filed: January 29, 2010
    Publication date: February 23, 2012
    Applicant: PROTAFFIN BIOTECHNOLOGIE AG
    Inventor: Andreas Kungl
  • USE OF MODIFIED INTERLEUKIN-8 PROTEINS FOR TREATING REPERFUSION INJURY OR TRANSPLANT REJECTION
    Publication number: 20110229433
    Abstract: The present invention relates to the use of a modified interleukin 8 (IL-8) having increased GAG binding affinity and further inhibited or down-regulated biological activity compared to the respective wild type IL-8 for preparing a medicament for the prevention and/or treatment of ischemia reperfusion injury and/or transplant rejection in patients.
    Type: Application
    Filed: August 28, 2007
    Publication date: September 22, 2011
    Applicant: Protaffin Biotechnologie AG
    Inventors: Andreas J. Kungl, Jens Bedke, Hermann-Josef Gröne
  • GAG BINDING PROTEIN
    Publication number: 20110144305
    Abstract: A method is provided for introducing a GAG binding site into a protein comprising the steps: identifying a region in a protein which is not essential for structure maintenance introducing at least one basic amino acid into said site and/or deleting at least one bulky and/or acidic amino acid in said site, whereby said GAG binding site has a GAG binding affinity of Kd?10 ?M, preferably ?1 ?M, still preferred ?0.1 ?M, as well as modified GAG binding proteins.
    Type: Application
    Filed: May 7, 2009
    Publication date: June 16, 2011
    Applicant: PROTAFFIN BIOTECHNOLOGIE AG
    Inventor: Andreas J. Kungl
  • GAG BINDING PROTEINS
    Publication number: 20100331237
    Abstract: A method is provided for introducing a GAG binding site into a protein comprising the steps: identifying a region in a protein which is not essential for structure maintenance introducing at least one basic amino acid into said site and/or deleting at least one bulky and/or acidic amino acid in said site, whereby said GAG binding site has a GAG binding affinity of Kd?10 ?M, preferably ?1 ?M, still preferred ?0.1 ?M, as well as modified GAG binding proteins.
    Type: Application
    Filed: August 18, 2010
    Publication date: December 30, 2010
    Applicant: PROTAFFIN BIOTECHNOLOGIE AG
    Inventor: Andreas J. KUNGL
  • SDF-I-BASED GLYCOSAMINOGLYCAN ANTAGONISTS AND METHODS OF USING SAME
    Publication number: 20100298203
    Abstract: The present invention relates to novel mutants of human stromal cell-derived factor-1 which exhibit increased glycosaminoglycan (GAG) binding affinity and inhibited or down-regulated GPCR activity compared to wild type SDF-1, methods for producing these mutants and to their use for preparing medicaments for the treatment of cancer.
    Type: Application
    Filed: October 23, 2008
    Publication date: November 25, 2010
    Applicant: PROTAFFIN BIOTECHNOLOGIE AG
    Inventors: Andreas Kungl, Isa Werner, Jason Slingsby, Simi Ali, John Kirby
  • GAG binding protein
    Patent number: 7807413
    Abstract: A method is provided for introducing a GAG binding site into a protein comprising the steps: identifying a region in a protein which is not essential for structure maintenance introducing at least one basic amino acid into said site and/or deleting at least one bulky and/or acidic amino acid in said site, whereby said GAG binding site has a GAG binding affinity of Kd?10 ?M, preferably ?1 ?M, still preferred ?0.1 ?M, as well as modified GAG binding proteins.
    Type: Grant
    Filed: June 2, 2008
    Date of Patent: October 5, 2010
    Assignee: Protaffin Biotechnologie AG
    Inventor: Andreas J. Kungl
  • Glycosaminoglycan-antagonising MCP-1 Mutants and Methods of Using Same
    Publication number: 20100197583
    Abstract: Novel mutants of human monocyte chemoattractant protein 1 (MCP-1) with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type MCP-1, and their use for therapeutic treatment of inflammatory diseases.
    Type: Application
    Filed: July 21, 2008
    Publication date: August 5, 2010
    Applicant: PROTAFFIN BIOTECHNOLOGIE AG
    Inventors: Andreas Kungl, Anna Maria Piccinini, Christian Weber
  • SYSTEM TO ASSESS THE BIOLOGICAL ACTIVITY OF CHEMOATTRACTANTS
    Publication number: 20100035294
    Abstract: The present invention relates to a system for measuring the biological activity of chemoattractants comprising at least two units separated by a semipermeable carrier wherein biologically active carbohydrate structures, preferably glycosaminoglycan (GAG) structures, are immobilized on the surface of said carrier. According to the invention, this system can be used for fast and economic measurement of the degree of cell mobility and chemotactic activity.
    Type: Application
    Filed: October 30, 2007
    Publication date: February 11, 2010
    Applicant: Protaffin Biotechnologie AG
    Inventor: Andreas J. Kungl
  • GAG binding proteins
    Patent number: 7585937
    Abstract: A method is provided for introducing a GAG binding site into a protein comprising the steps: identifying a region in a protein which is not essential for structure maintenance introducing at least one basic amino acid into said site and/or deleting at least one bulky and/or acidic amino acid in said site, whereby said GAG binding site has a GAG binding affinity of Kd?10 ?M, preferably 1 ?M, still preferred ?0.1 ?M, as well as modified GAG binding proteins.
    Type: Grant
    Filed: June 5, 2006
    Date of Patent: September 8, 2009
    Assignee: Protaffin Biotechnologie AG
    Inventor: Andreas J. Kungl
  • GAG BINDING PROTEIN
    Publication number: 20090005541
    Abstract: A method is provided for introducing a GAG binding site into a protein comprising the steps: identifying a region in a protein which is not essential for structure maintenance introducing at least one basic amino acid into said site and/or deleting at least one bulky and/or acidic amino acid in said site, whereby said GAG binding site has a GAG binding affinity of Kd?10 ?M, preferably ?1 ?M, still preferred ?0.1 ?M, as well as modified GAG binding proteins.
    Type: Application
    Filed: June 2, 2008
    Publication date: January 1, 2009
    Applicant: PROTAFFIN BIOTECHNOLOGIE AG
    Inventor: Andreas J. KUNGL
  • GAG BINDING PROTEINS
    Publication number: 20080112926
    Abstract: A method is provided for introducing a GAG binding site into a protein comprising the steps: identifying a region in a protein which is not essential for structure maintenance introducing at least one basic amino acid into said site and/or deleting at least one bulky and/or acidic amino acid in said site, whereby said GAG binding site has a GAG binding affinity of Kd?10 ?M, preferably ?1 ?M, still preferred ?0.1 ?M, as well as modified GAG binding proteins.
    Type: Application
    Filed: June 5, 2006
    Publication date: May 15, 2008
    Applicant: PROTAFFIN BIOTECHNOLOGIE AG
    Inventor: Andreas J. Kungl